Results 11 to 20 of about 120,548,321 (260)
Electrical Stimulation of Injected Muscles to Boost Botulinum Toxin Effect on Spasticity: Rationale, Systematic Review and State of the Art [PDF]
Toxins, 2021 Botulinum toxin type A (BoNT-A) represents a first-line treatment for spasticity, a common disabling consequence of many neurological diseases. Electrical stimulation of motor nerve endings has been reported to boost the effect of BoNT-A. To date, a wide
Alessandro Picelli +6 more
doaj +3 more sources
Botulinum toxin type A versus botulinum toxin type B for cervical dystonia [PDF]
Cochrane Database of Systematic Reviews, 2016 This is an update of a Cochrane review first published in 2003. Cervical dystonia is the most common form of focal dystonia and is a disabling disorder characterised by painful involuntary head posturing. There are two available formulations of botulinum toxin, with botulinum toxin type A (BtA) usually considered the first line therapy for this ...
Duarte, GS +7 more
+9 more sources
The Structure and Classification of Botulinum Toxins
, 2021 Botulinum neurotoxins (BoNTs) are a family of bacterial protein toxins produced by various Clostridium species. They are traditionally classified into seven major serotypes (BoNT/A-G).
Stenmark, Pål, +2 more
core +2 more sources
Harnessing the Membrane Translocation Properties of AB Toxins for Therapeutic Applications [PDF]
, 2021 Over the last few decades, proteins and peptides have become increasingly more common as FDA-approved drugs, despite their inefficient delivery due to their inability to cross the plasma membrane.
Oksana A. Sergeeva +2 more
core +2 more sources
Botulinum toxin type A therapy for blepharospasm [PDF]
Cochrane Database of Systematic Reviews, 2020 This is an update of a Cochrane Review first published in 2005. Blepharospasm is the second most common form of focal dystonia. It is a disabling disorder, characterised by chronic, intermittent or persistent, involuntary eyelid closure, due to spasmodic contractions of the orbicularis oculi muscles.
Duarte, GS +7 more
openaire +5 more sources
Botulinum Toxin as Preventive Treatment for Migraine: A Randomized Double-Blind Study [PDF]
, 2009 Aim: To determine if botulinum toxin type A (BoNT-A) injections can reduce the frequency and severity of migraines. Methods: Patients (n = 127) were randomized to receive placebo or two doses of BoNT-A (Dysport (R)). The primary endpoint was reduction in
Toelle, Thomas +13 more
core +1 more source
Botulinum toxin type A for the management of glabellar rhytids [PDF]
, 2010 Anne Marie Tremaine, Jerry L McCulloughDepartment of Dermatology, University of California, Irvine, CA, USAAbstract: There is an increasing demand for minimally-invasive cosmetic procedures to arrest the aging process.
Tremaine, Anne Marie +3 more
core +1 more source
Botulinum Toxin Type a in Cervical Dystonia
International Journal of Immunopathology and Pharmacology, 2012 Cervical dystonia is a syndrome characterized by anomalous postures and unintentional repetitive movements of the head and the neck. Aim of this study is to show the effectiveness of the combined treatment botulinum toxin-FKT through the use of a recent methodic of investigation, myoton, and of the classical clinical evaluations, such as Tsui and VAS ...
Marvulli R. +7 more
openaire +3 more sources
ABCS Health Sciences, 2022 Introduction: The use of botulinum toxin type A (BTX-A) to correct gummy smile has become popular in recent years. Objective: To evaluate the effects of BTX-A application in the correction of gummy smile 2 and 32 weeks after application.
Carlos Eduardo Alonso Vieira +7 more
doaj +1 more source
Clostridium botulinum Type E Toxins Bind to Caco-2 Cells by a Different Mechanism from That of Type A Toxins [PDF]
, 2012 Cultured Clostridium botulinum strains produce progenitor toxins designated as 12S, 16S, and 19S toxins. The 12S toxin consists of a neurotoxin (NTX, 7S) and a non-toxic non-hemagglutinin (NTNH).
Oguma, Keiji +6 more
core +1 more source